Irish clinical stage biopharma group Amarin has announced it has successfully completed non-clinical studies ahead of a planned new drug application to the US authorities for its drug which tackles high blood fats.

AMR101 has previously reported strong trial results in treating patients with very high triglycerides, a factor in coronary heart disease.